Nautilus Biotechnology Inc. has entered into a research collaboration with Weill Cornell Medicine-Qatar and The Michael J. Fox Foundation for Parkinson's Research to advance single-molecule proteomics research in Parkinson’s disease. Supported by a $1.6 million grant from The Michael J. Fox Foundation, the partnership aims to study the connection between the alpha-synuclein protein and Parkinson's disease. The project will leverage Nautilus’ innovative single-molecule proteome analysis platform and Weill Cornell Medicine-Qatar’s expertise in neurodegeneration to develop novel assays for precise mapping of alpha-synuclein proteoforms, with the goal of advancing diagnostics and therapies for Parkinson’s disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nautilus Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9644046-en) on January 28, 2026, and is solely responsible for the information contained therein.